MedTrace Logo

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

NCT01001403 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2010-05-11

Study results available
· View outcomes & findings →

Summary

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Conditions

  • Liver Transplantation
  • Postreperfusion Syndrome

Interventions

DRUG

Nafamostat

0.2 mg/kg as bolus 1 minute before reperfusion

DRUG

Normal saline

10 ml of normal saline

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001403 on ClinicalTrials.gov